Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

R. Oxnard, Geoffrey; S. Thress, Kenneth; S. Alden, Ryan; Lawrance, Rachael; P. Paweletz, Cloud; Cantarini, Mireille; Chih‐Hsin Yang, James; Carl Barrett, J.; A. Jänne, Pasi

doi:10.1200/jco.2016.66.7162

Public

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

Published in Journal of Clinical Oncology • Jun 29, 2016

Authors:

Geoffrey R. Oxnard

Kenneth S. Thress

Ryan S. Alden

Abstract

PURPOSE: Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have demonstrated potent activity against TKI resistance mediated by EGFR T790M. We studied whether noninvasive genotyping of cell-free plasma DNA (cfDNA) is a useful biomarker for prediction of outco...

Subject

T790M

Osimertinib

Genotyping

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!